triazolam has been researched along with Intertrochanteric Fractures in 1 studies
Triazolam: A short-acting benzodiazepine used in the treatment of insomnia. Some countries temporarily withdrew triazolam from the market because of concerns about adverse reactions, mostly psychological, associated with higher dose ranges. Its use at lower doses with appropriate care and labeling has been reaffirmed by the FDA and most other countries.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (100.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Wysowski, DK | 1 |
| Baum, C | 1 |
| Ferguson, WJ | 1 |
| Lundin, F | 1 |
| Ng, MJ | 1 |
| Hammerstrom, T | 1 |
1 other study available for triazolam and Intertrochanteric Fractures
| Article | Year |
|---|---|
Sedative-hypnotic drugs and the risk of hip fracture.
Topics: Accidental Falls; Aged; Aged, 80 and over; Anti-Anxiety Agents; Cohort Studies; Female; Florida; Hip | 1996 |